GLMDGalmed Pharmaceuticals Ltd

Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market PR Newswire RAMAT GAN, Israel, June 8, 2026 Transaction will add FDA Breakthrough...

Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of...

Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA...

Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics Tissue Dynamics and Galmed Pharmaceuticals to Develop...

Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for...

Galmed Pharmaceuticals Ltd. shares are trading higher after it announced the development of a brain penetrating new formulation of Aramchol.read more...

A wave of innovation across AI robotics, biotechnology, advanced materials, and clean energy is reshaping the small-cap landscape. $ONCO, $KBLB, $ELAB, $GLMD, $TURB, $GAME

The biotech firm launched a new formulation of its investigational therapy, which could help treat Parkinson’s disease.

Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol Galmed Announces the Breakthrough Development of a Brain Penetrating New...